|
ATG2B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.37443398276582E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.11561887400558E-12 |
| Normal-vs-Stage2 |
2.10830000013651E-07 |
| Normal-vs-Stage3 |
4.44089209850063E-16 |
| Normal-vs-Stage4 |
2.49866793922138E-12 |
| Stage1-vs-Stage2 |
8.740100E-02 |
| Stage1-vs-Stage3 |
1.935600E-01 |
| Stage1-vs-Stage4 |
1.637760E-01 |
| Stage2-vs-Stage3 |
2.442100E-02 |
| Stage2-vs-Stage4 |
2.139600E-02 |
| Stage3-vs-Stage4 |
7.411800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.73479025483903E-13 |
| Normal-vs-AfricanAmerican |
1.7852999999457E-06 |
| Normal-vs-Asian |
1.60239599367173E-11 |
| Caucasian-vs-AfricanAmerican |
3.761400E-01 |
| Caucasian-vs-Asian |
8.210800E-01 |
| AfricanAmerican-vs-Asian |
4.519800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.67297295408753E-12 |
| Normal-vs-Female |
2.5649482537915E-12 |
| Male-vs-Female |
7.808400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.45212747276946E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
4.90385509976932E-12 |
| Normal-vs-Age(81-100Yrs) |
1.798690E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.223400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.460600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.589800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.965800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.590600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.297200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.90320000000144E-05 |
| Classical-VS-Follicular |
3.336400E-01 |
| Classical-VS-Other |
2.520800E-01 |
| Classical-VS-Normal |
1.92700300161164E-11 |
| Tall-VS-Follicular |
7.68700000000067E-05 |
| Tall-VS-Other |
5.396400E-01 |
| Tall-VS-Normal |
1.4432899320127E-15 |
| Follicular-VS-Other |
2.051200E-01 |
| Follicular-VS-Normal |
6.15040018914215E-10 |
| Other-VS-Normal |
1.798930E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
9.76496661309056E-12 |
| N0-vs-N1 |
3.623400E-01 |
|
|
